A stroke is a form of brain injury caused by blood supply to the brain being interrupted. This medical emergency requires prompt treatment; responding too late increases the likelihood of brain damage.
Figures show that strokes are the third leading cause of death and disability around the globe, with billions in funds being allocated for long-term healthcare services, support and rehabilitation for stroke survivors. Long-term rehabilitation is usually exhaustive and lengthy, highlighting the need for a new treatment approach, especially since traditional stroke treatments are not 100% effective.
This may be realized sooner than we thought. Algernon Pharmaceuticals announced last month that it plans to conduct a phase I study looking into the use of DMT infusions for stroke.
A consultant of the company, Dr. David Nutt, stated that Algernon’s approach with DMT strengthened the natural recovery of the brain by improving neuroplasticity, which in turn facilitated the development of new neural networks. Nutt, who is also a neuropsychopharmacology professor at Imperial College London, added that this new approach was different from anything that had been tried previously.
DMT, or N,N-Dimethyltryptamine, is a hallucinogenic drug known to produce effects similar to psilocybin and LSD. This strong psychedelic is produced in a range of animal and plant species, in addition to being found in minute quantities in the human body.
However, unlike other psychedelics, DMT delivers a visually intense and almost instant trip that lasts anywhere from 30 to 45 minutes. Prior studies have shown that this psychedelic compound may provide unique therapeutic benefits as a treatment for stroke.
Algernon CEO Christopher Moreau believes that this compound represents a new way to promote recovery and healing after a patient experiences an ischemic stroke, which is a common type of stroke. The company has been conducting research on DMT’s viability as a stroke treatment for more than a year, with its earlier findings showing that the compound stimulated growth of neuron cells by 40%.
Moreau revealed that the company’s upcoming trial would focus on studying the effects of administering small doses of DMT to human participants. Algernon’s phase I trial is set to kick off in the last quarter of this year in the Netherlands. It will involve no more than 60 volunteers and will test the safety, tolerability and pharmacokinetics of DMT.
This trial is unique because the psychedelic compound will be administered to participants as slow-release IV infusions, which allows it to enter the bloodstream immediately and circulate in the body.
Currently, a number of jurisdictions allow ketamine infusions, and companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have several centers that are operational in this regard; the centers also conduct development programs involving other psychedelic compounds with known medicinal potential.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
